Press Release Archive

02.03.2026

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

02.03.2026

Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

01.10.2026

Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

01.05.2026

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

12.18.2025

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

12.17.2025

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

12.16.2025

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

12.12.2025

Pfizer Declares First-Quarter 2026 Dividend

12.10.2025

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

12.09.2025

Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

12.06.2025

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

12.01.2025

European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA™ (pembrolizumab) for Certain Patients with Muscle-Invasive Bladder Cancer